Skip to main content
. 2022 Apr 1;13(6):e00492. doi: 10.14309/ctg.0000000000000492

Table 4.

Summary of virological response

Median HCV-RNA log10 FC at day 14 (end of treatment) HCV-RNA reduction ≥1 log10 at day 14 (end of treatment) Median HCV-RNA log10 FC at day 28 (end of follow-up) HCV-RNA reduction ≥0.5 log10 at day 28 (end of follow-up) HCV-RNA reduction ≥1 log10 at day 28 (end of follow-up)
Placebo (n = 3, pooled data) 0.08 0 0.06 0 0
Erlotinib 50 mg (n = 3) −0.03 0 0.27 1 0
Erlotinib 100 mg (n = 3) −0.12 0 −0.76 2 1

FC, fold changes; HCV, hepatitis C virus.